Skip to main content
OpenTrials
Completed

NCT Number: NCT03313817

Pre and Post-arterial Recanalization Imaging of Central Retinal Artery Occlusions (CRAO)

Central retinal artery occlusions (CRAO) are the equivalent of an ischemic stroke at the retinal level. They share the same risk factors and common pathology. The diagnosis of a CRAO is clinically based on the sudden occurrence of a decrease in deep visual acuity with fundamentally signs of reactive ischemia.

Small studies have highlighted the value of cerebral MRI (Magnetic Resonance Imaging) in CRAO with almost 25% of ischemic strokes found on diffusion sequences and the demonstration of a correlation between anomalies in diffusion sequence and the probability of a pathology with a high risk of recurrence (carotid stenosis or emboligenic cardiopathy). But there are usually few radiological signs that allow a direct positive diagnosis of CRAO, an etiologic diagnosis or a prognosis. This descriptive study will focus on CRAO at the diagnostic and post-treatment phases in the short and medium term, in order to (i) identify imaging etiologic signs of CRAO with specific sequences from a 3 Tesla MRI, (ii) identify positive diagnostic signs of CRAO with the same specific sequences, (iii) correlate these signs with the visual prognosis one month after the CRAO.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Fondation Ophtalmologique A. de Rothschild

Paris, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 years of age or older
  • CRAO (onset of symptoms ≤ 48 hours)
  • Consent to participate in the study

Exclusion criteria

  • Contraindications to 3 Tesla MRI

Treatment and study plan

Additional MRI sequences

Device

Patients will be hospitalized for suspicion of CRAO. An "optimized" MRI will be performed with specific sequences: 3D T1 MSDE (Motion Sensitized Driven Equilibrium) "dark blood"; 3D Optimized diffusion centered on the optic nerves; 3D PD T1 after injection. A consultation of ophthalmology and a control MRI will be carried out one month after the CRAO. Again, specific sequences will be added: 3D T1 MSDE (Motion Sensitized Driven Equilibrium) "dark blood"; 3D Optimized diffusion centered on the optic nerves; DTI (Diffusion Tensor Imaging); 3D PD T1 after injection.

Primary outcomes

  1. Contrast enhancement of the ophthalmic artery

    Time frame: Baseline

    Binary variable (yes/no)

  2. Presence of a thrombus

    Time frame: Baseline

    Binary variable (yes/no)

  3. Presence of an arterial stenosis of the supra aortic trunks

    Time frame: Baseline

    Binary variable (yes/no)

  4. Hypersignal of the ophthalmic artery in diffusion

    Time frame: Baseline

    Binary variable (yes/no)

  5. Restriction of the apparent diffusion coefficient (ADC) at the optic nerve level and at the papilla level

    Time frame: Baseline

    Binary variable (yes/no)

Sponsors and collaborators

Lead sponsor

Fondation Ophtalmologique Adolphe de Rothschild

Network

Registry information

Acronym: I-RECANAL

Important dates

Study start
2017
Primary completion
2023
Study completion
2024
First posted
Oct 18, 2017
Registry last updated
Jan 5, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.